Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 193(2018) vom: 25. Aug., Seite 24-32
1. Verfasser: Lord, James D (VerfasserIn)
Weitere Verfasser: Long, S Alice, Shows, Donna M, Thorpe, Jerill, Schwedhelm, Katherine, Chen, Janice, Kita, Mariko, Buckner, Jane H
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Crohn's disease FOXP3 Helios IL-2, IL-6, IL-7, IL-21 Integrin Stat Th1 mehr... Th2 Treg Vedolizumab cT(FH) Antibodies, Monoclonal, Humanized CXCR5 protein, human Cytokines FOXP3 protein, human Forkhead Transcription Factors Gastrointestinal Agents IKZF2 protein, human Inflammation Mediators Integrins Receptors, CXCR5 integrin alpha4beta7 Ikaros Transcription Factor 148971-36-2 vedolizumab 9RV78Q2002